Interruptions of antiretroviral therapy in human immunodeficiency virus infection : are they detrimental to neurocognitive functioning?
Muñoz-Moreno, Jose Antonio (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Fumaz, Carmina R. (Rodríguez Fumaz) (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Prats, Anna (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Ferrer, Maria J. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Moltó, José (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Gómez Melis, Guadalupe (Universitat Politècnica de Catalunya)
Garolera i Freixa, Maite (Consorci Sanitari Hospital de Terrassa)
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Universitat Autònoma de Barcelona

Date: 2010
Abstract: Background: Since interruptions of antiretroviral treatment may entail clinical risks for HIV-infected individuals, we investigated their impact on neurocognitive functioning. Methods: Cross-sectional study comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (non-interruption group, NIG). Interruption was defined as the discontinuation of HAART for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. Results: A total of 83 subjects participated in the study (IG: n=27, NIG: n=56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13. 8; NIG, 10. 2 [p=0. 003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59. 25%; NIG, 33. 92% [p=0. 02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. Conclusions: In our study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning.
Note: Número d'acord de subvenció FIPSE/2355/02
Note: Número d'acord de subvenció MICINN/MTM2008-06747-C02-00
Note: Número d'acord de subvenció ISCIII/RETICS/RD06/0006
Rights: Tots els drets reservats
Language: Anglès.
Document: article ; recerca ; acceptedVersion
Subject: Antiretroviral therapy ; HIV infection ; Neurocognitive functioning ; Neuropsychological assessment ; Treatment interruption
Published in: Journal of Neurovirology, Vol. 16, Issue 3 (May 2010) , p. 208-218, ISSN 1355-0284



Post-print
19 p, 76.2 KB

Figura 1
1 p, 11.3 KB

Figura 2
1 p, 137.1 KB

Taula 1
1 p, 14.4 KB

Taula 2
1 p, 59.2 KB

Taula 3
1 p, 15.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles

 Record created 2015-11-11, last modified 2019-02-11



   Favorit i Compartir